ABSTRACT

1. Immune mapped protein-1 (IMP1) of E. maxima has been identified as a vaccine antigen candidate for E. maxima infection.

2. In the current study, the N- and C-terminal derivative of EmIMP1 were expressed in E. coli and administered to chickens. The antibody response, cell-mediated immune (CMI) response and the protective efficacy of the protein vaccines against E. maxima challenge were evaluated.

3. The results showed that C-terminal derivative of EmIMP1 vaccination could increase weight gain, reduce enteric lesions, and decrease faecal oocysts shedding. Moreover, the C-terminal derivative of EmIMP1 caused reasonable improvement in serum antibodies and the numbers of IFN-γ producing peripheral blood mononuclear cells (PBMC), as compared to the control group.

4. This study demonstrated that the C-terminal derivative of EmIMP1 could be used as a potent immunogenic candidate in the development of subunit vaccines against E. maxima infection.

摘要

1.免疫映射的蛋白-1（IMP1）E.最大值已被确定作为疫苗抗原候选巨型艾美球虫感染。

2.在当前的研究中，EmIMP1的N和C末端衍生物在大肠杆菌中表达并施用于鸡。评估了抗体反应，细胞介导的免疫（CMI）反应和蛋白疫苗对最大大肠杆菌的攻击的保护作用。

3.结果表明，EmIMP1疫苗的C末端衍生物可增加体重，减少肠内损害，并减少粪便卵囊脱落。此外，与对照组相比，EmIMP1的C末端衍生物可合理改善血清抗体和产生IFN-γ的外周血单个核细胞（PBMC）的数量。

4.本研究证实EmIMP1的C-末端衍生物可以用作在针对亚单位疫苗的开发的有力的免疫原性候选巨型艾美球虫感染。